


VISION 2025

2025

10/16-17
ARLINGTON VA, USA



#VISION2025 VISIONCONSENSUS.COM



VISION

Vascular Intervention & Stroke Innovation through Neuroimaging

October 16 - 17, 2025

Arlington VA

Mission:

The primary objective of the **Vascular Intervention & Stroke Innovation thrOugh Neuroimaging (VISION)** is to establish a diverse platform where experts from both the public and private sectors can collaborate, share their expertise, and reach a consensus on strategies aimed at enhancing vascular intervention and stroke innovation through neuroimaging. VISION aims to foster advancements in research studies and clinical practice in this field. To achieve this, VISION will facilitate a comprehensive multidisciplinary collaboration involving key clinical disciplines such as neurosurgeons, neuroendovascular surgeons, neurointerventional radiologists, and neurologists.

Who is involved:

VISION architecture thus includes 3 major stakeholders research and practice in the field of vascular intervention and stroke innovation through neuroimaging: academia (leading international physicians/scientists from all involved disciplines), industry (scientists and executives from private sector pharmaceutical, device, and imaging companies), and regulatory institutions (executive managers, physicians and scientists from NIH and FDA).

PRELIMINARY AGENDA:

The **VISION** program begins with a full-day conference that offers a comprehensive exploration of cutting-edge neuroimaging technologies and their application in stroke diagnosis, treatment, and management. It is divided into four focused sessions, each addressing crucial aspects of stroke care emphasizing the latest advancements in clinical and research methodologies. The agenda includes:

- **SESSION 1: MOBILE NEURODIAGNOSTICS FOR STROKE DETECTION AND MANAGEMENT**

This session delves into the evolving paradigms of stroke diagnosis in prehospital and ICU settings, emphasizing the critical role of mobile imaging

- 🌀 *PREHOSPITAL AND ICU PARADIGMS FOR STROKE DIAGNOSES*
- 🌀 *MOBILE USE OF STANDARD IMAGING: PREHOSPITAL CT IMAGING*
- 🌀 *MOBILE USE OF STANDARD IMAGING: MRI IMAGING IN THE ICU*

- **SESSION 2: ACUTE ISCHEMIC STROKE CHARACTERIZATION AND QUANTIFICATION**

This session evaluates the importance of stroke volume quantification and imaging approaches

- 🌀 *TO QUANTIFY OR NOT TO QUANTIFY: DOES SIZE MATTER?*
- 🌀 *STROKE CHARACTERIZATION AND QUANTIFICATION: CT APPROACH*
- 🌀 *STROKE CHARACTERIZATION AND QUANTIFICATION: MRI APPROACH*

- **SESSION 3: NEUROIMAGING EVALUATION IN THERAPEUTIC DRUG/DEVIC DEVELOPMENT**

Focuses on how neuroimaging informs therapeutic innovation and clinical trial design

- 🌀 *WHICH ONE MATTERS MOST: THERAPEUTIC RESPONSE OR CLINICAL OUTCOME*

🌀 **USE OF AUTOMATED AND STANDARD IMAGING INTERPRETATION TO PREDICT THERAPEUTIC RESPONSE**

🌀 **IMAGING CORE LAB METHODOLOGY AND FUNCTIONS FOR CLINICAL TRIALS**

- **SESSION 4: NEUROIMAGING OF HEMORRHAGIC TRANSFORMATION**

Addresses the imaging and clinical management of hemorrhagic transformation (HT), a significant complication in stroke therapy

🌀 **DEFINITIONS OF HEMORRHAGIC TRANSFORMATION: WHAT MATTERS?**

🌀 **IMAGING OF HEMORRHAGIC TRANSFORMATION: IMPLICATIONS FOR CLINICAL PRACTICE**

🌀 **BALANCING SAFETY: THE ROLE OF DEVICES AND DRUGS IN HEMORRHAGIC TRANSFORMATION**

The **second** day of VISION focuses on developing consensus recommendations through a collaborative process involving experts from academia, industry, and regulatory institutions. Here's how the day is structured:

Participants are divided into three thematic groups, focusing on:

🌀 **WORKSHOP 1: MOBILE STROKE DIAGNOSIS**

🌀 **WORKSHOP 2: STROKE IMAGING MEASURE OF THERAPEUTIC IMPACT**

🌀 **WORKSHOP 3: EVOLVING DEFINITIONS OF HEMORRHAGIC TRANSFORMATION**

CONSENSUS STATEMENT PREPARATIONS

Each group is provided equal opportunity to engage in structured discussions. Initial recommendations from academic leaders in these fields are presented. These are then openly discussed, amended or expanded based on group input and replaced or refined as necessary. Each group presents their finalized recommendations to the entire assembly for broader input and validation. Writing Committees draft manuscripts summarizing the group recommendations.

Drafts are reviewed by all participants. Finalized articles are published to disseminate the recommendations widely.

This process ensures that the consensus reflects a balanced, multidisciplinary perspective, promoting evidence-based, actionable guidelines.

Invitation:

VISION is a Roundtable where only invited faculty and companies can participate.

The goal is to have companies from different fields involved.

VISION is *inviting* your company to participate in this meeting by supporting this excellent platform that has a goal to enhancing vascular intervention and stroke innovation through neuroimaging.

You have the possibility to bring your company's representatives, according to your support level:

✚ **Platinum – USD 40 000** – up to 8 representatives throughout the meeting including consensus statement preparation; 2 representatives as faculty discussants during sessions on day 1.

✚ **Gold – USD 30 000** – 4-5 representatives throughout the meeting including consensus statement preparation; 1 representative as faculty discussant during 1 session on the first day.

✚ **Silver – USD 20 000** – 2-3 representatives throughout the meeting including consensus statement preparation.

✚ **Bronze – USD 10 000** – up to 2 representatives throughout the meeting including consensus statement preparation.

CORE ORGANISERS:



**David S Liebeskind,
MD, FAHA, FAAN, FANA, FSVIN, FWSO**

Professor of Neurology at the University of California, Los Angeles (UCLA) where he is Director of the UCLA Stroke Center.



**Max Wintermark,
MD, MS, MBA**

Professor and the Chair of Neuroradiology at the University of Texas MD Anderson Center

FOR FURTHER DETAILS, PLEASE CONTACT ME:



MARIETA TSENEVA

Industry Liaison & Sales Associate

E: mtseneva@kenes.com | T: +41 22 908 0488 Ext. 273

Funding

Please note, VISION does not receive any government funding.

VISION conferences are funded solely by participating private sector companies.